Beractant Phospholipids: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Beractant Phospholipids. Educational only — not medical advice.
Reported adverse reactions
| Reaction | Highest frequency reported* |
|---|---|
| Apnea | 65.4% |
| Intracranial hemorrhage | 48.1% |
| Patent ductus arteriosus | 47.1% |
| Severe apnea | 46.1% |
| Pulmonary interstitial emphysema | 38.4% |
| Pulmonary air leaks | 24.7% |
| Severe intracranial hemorrhage | 24.1% |
| Post-treatment sepsis | 20.7% |
| Post-treatment infection | 10.2% |
| Pulmonary hemorrhage | 7.2% |
| Necrotizing enterocolitis | 6.1% |
*Highest percentage across placebo-controlled trial tables summarized in current labeling.
Labeled uses
SURVANTA is indicated for prevention and treatment (“rescue”) of Respiratory Distress Syndrome (RDS) (hyaline membrane disease) in premature infants.
Source: FDA labeling via NIH DailyMed (set 7ef9e3a5…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.